Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Genetron Holdings $256 million IPO
Davis Polk advised Genetron Holdings Limited on its SEC-registered initial public offering of 16,000,000 American Depositary…
IVERIC bio $160 million stock and warrants offering and private placement
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a…
IDEAYA Biosciences $100 million follow-on offering
Davis Polk advised the underwriters in connection with a public offering of 6,666,667 shares of common stock of IDEAYA…
Constellation Pharmaceuticals $192.5 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the …
Shockwave Medical $89.4 million stock offering
Davis Polk advised Shockwave Medical, Inc. on its SEC-registered public offering of 1,955,000 shares of common stock for an…
Royalty Pharma $2.5 billion IPO
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering…
Generation Bio $230 million IPO
Davis Polk advised the representatives of the underwriters in connection with the $230 million initial public offering…
Applied Therapeutics $100 million at-the-market offering
Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Applied Therapeutics,…
ChemoCentryx $346.8 million follow-on offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 5…
Jazz Pharmaceuticals $850 million exchangeable senior notes offering
Davis Polk advised the initial purchasers on a Rule 144A offering by Jazz Investments I Limited, a wholly owned…